Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer: a phase 3 randomized controlled trial (NATALEE)

Breast Cancer Research · Published 2026-08-04 · DOI 10.1186/s13058-026-02352-2

Free full text

Authors (17)

H. S. Rugo, N. Harbeck, G. N. Hortobagyi, J. O’Shaughnessy, C.-S. Huang, M. Martin, D. Juric, B. Pistilli, B. Xu, M. De Laurentiis, M. Untch, K. Afenjar, M. Gao, Z. Li, N. Bolotova, S. Waters, C. Barrios

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Rugo, H., Harbeck, N., Hortobagyi, G., et al. (2026). Safety and treatment duration of ribociclib + nonsteroidal aromatase inhibitor in HR+/HER2− early breast cancer: a phase 3 randomized controlled trial (NATALEE). Breast Cancer Research. https://doi.org/10.1186/s13058-026-02352-2

Related articles

• Artificial intelligence integrated multi-omics and multimodal studies promote the efficacy of neoadjuvant chemotherapy in breast cancer: opportunities, challenges, and future perspectives · Breast Cancer Research · 2026 · Same journal
• Targeting drug resistance in breast cancer: a dual-perspective landscape analysis of PROTACs from bench to bedside · Breast Cancer Research · 2026 · Same journal
• Predicting sentinel lymph node metastasis in breast cancer using an interpretable machine learning approach based on multi-domain clinical features · Breast Cancer Research · 2026 · Same journal
• CAF-derived exosomes drive trastuzumab resistance in HER2-positive breast cancer via YAP-USP8-HER2 axis activation · Breast Cancer Research · 2026 · Same journal
• Reduction of primary tumor growth and metastasis in models of triple-negative breast cancer following tilorone administration via type I interferon signaling · Breast Cancer Research · 2026 · Same journal
• The association between adiposity and cardiac function in patients with early breast cancer receiving cardiotoxic therapies · Breast Cancer Research · 2026 · Same journal
• Time-dependent anti-Müllerian hormone dynamics during GnRHa-based endocrine therapy in young breast cancer survivors: a longitudinal real-world cohort study · Breast Cancer Research · 2026 · Same journal
• Vascular and mesenchymal signatures of breast cancers associated with Yo and Ri paraneoplastic syndrome · Breast Cancer Research · 2026 · Same journal
• LMAN2 promotes breast cancer progression and deduces cell sensitivity to doxorubicin through stearoyl-CoA desaturase · Breast Cancer Research · 2026 · Same journal
• Transcriptome predictors of second breast events in ductal carcinoma in situ: a case‒control study including Black and White women · Breast Cancer Research · 2026 · Same journal